The MDM2 inhibitors MI-77301 and NVP-CGM097 were tested against patient derived models of p53 wild type, fulvestrant-resistant ER+ breast cancer by Lu and colleagues (46) and by us (29) respectively. This evidence concerns the gene MDM2 and breast carcinoma.